The IMMUNOASPECT project aims to study allergic bronchopulmonary aspergillosis (ABPA) in the context of cystic fibrosis (CF). ABPA, which is caused by the fungus Aspergillus fumigatus, has been associated with the severity of lung disease in CF, however the connections between airway inflammation, impaired lung function and immune response remain poorly understood. IMMUNOASPECT is based on the need to facilitate a prompt diagnosis of ABPA in the pediatric patient with cystic fibrosis, by identifying diagnostic markers. CF patients will be recruited from the G. Tatarella hospital in Cerignola (BA) and the Ospedale Pediatrico Bambino Gesù in Rome to measure the concentration of the antibodies (IgG and IgE immunoglobulins) and correlate it to the Aspergillus infection. In addition, the interleukins (ILs) released, which are proteins produced by the immune system in response to an infection, will be evaluated for each CF patient. Some ILs such as IL-17F and IL-17RC are able to activate Aspergillus specific antibodies and counteract the fungal infection. The understanding of the function of the different subclasses of specific fungus immunoglobulins and the analysis of the respective IL released can represent a valid tool to improve the diagnosis and therapy of ABPA in the pediatric patient with CF. IMMUNOASPECT’s long-term goal is to advance in the development and refinement of therapies based on monoclonal applications for the treatment of respiratory infectious diseases.